TY - JOUR
T1 - Associations of fibroblast growth factor 23 with urate metabolism in patients with chronic kidney disease
AU - Sakoh, Teppei
AU - Nakayama, Masaru
AU - Tsuchihashi, Takuya
AU - Yoshitomi, Ryota
AU - Tanaka, Shigeru
AU - Katafuchi, Eisuke
AU - Fukui, Akiko
AU - Shikuwa, Yui
AU - Anzai, Naohiko
AU - Kitazono, Takanari
AU - Tsuruya, Kazuhiko
N1 - Funding Information:
A total of 606 patients were admitted to our hospital for the evaluation and education of CKD between June 2009 and January 2016. Patients with no available data for blood and urine samples and who experienced acute exacerbation of kidney function were excluded (n = 69). The remaining 537 were enrolled in this cross-sectional study. All patients provided written informed consent to the protocol, which was approved by the Ethics Committee of the National Hospital Organization Kyushu Medical Center, and the study was registered in the University Hospital Medical Information Network (UMIN) clinical trial registry (UMIN, #000,020,652). 2.2
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Objective In patients with preserved kidney function, a positive association of fibroblast growth factor 23 (FGF23) with serum uric acid (SUA) has been reported; however, the relationship in overall chronic kidney disease (CKD) patients has not been investigated. No report has examined the relationship between FGF23 and uric acid clearance (CUA). The aim of the present study was to determine whether FGF23 is independently associated with urate metabolism in patients with CKD stages 1–5. Materials and methods In this cross-sectional study, 537 CKD patients were enrolled. SUA, CUA, FGF23, parathyroid hormone (PTH), and 1,25-dihydroxyvitamin D (1,25(OH)2D) were measured. Multivariable linear regression analysis was applied to determine independent factors associated with SUA or CUA. Results In all patients, both SUA and CUA were independently associated with male sex, use of diuretics, use of uric acid-lowering agents, estimated glomerular filtration rate, and log FGF23 (β = 0.29, P < 0.01 for SUA; β = − 0.11, P < 0.01 for CUA), but not with log PTH or log 1,25(OH)2D. Dyslipidemia and diabetes were also independent factors for SUA and CUA, respectively. In multivariable analyses by sex, log FGF23 was associated with SUA in both sexes (β = 0.32, P < 0.01 in males vs. β = 0.20, P = 0.02 in females). Conversely, log FGF23 was independently associated with CUA in males (β = − 0.15, P < 0.01), but not in females (β = − 0.09, P = 0.17). Conclusions FGF23 was independently associated with urate metabolism in this population of CKD patients. FGF23 might also have a stronger association with urate metabolism in males compared with females.
AB - Objective In patients with preserved kidney function, a positive association of fibroblast growth factor 23 (FGF23) with serum uric acid (SUA) has been reported; however, the relationship in overall chronic kidney disease (CKD) patients has not been investigated. No report has examined the relationship between FGF23 and uric acid clearance (CUA). The aim of the present study was to determine whether FGF23 is independently associated with urate metabolism in patients with CKD stages 1–5. Materials and methods In this cross-sectional study, 537 CKD patients were enrolled. SUA, CUA, FGF23, parathyroid hormone (PTH), and 1,25-dihydroxyvitamin D (1,25(OH)2D) were measured. Multivariable linear regression analysis was applied to determine independent factors associated with SUA or CUA. Results In all patients, both SUA and CUA were independently associated with male sex, use of diuretics, use of uric acid-lowering agents, estimated glomerular filtration rate, and log FGF23 (β = 0.29, P < 0.01 for SUA; β = − 0.11, P < 0.01 for CUA), but not with log PTH or log 1,25(OH)2D. Dyslipidemia and diabetes were also independent factors for SUA and CUA, respectively. In multivariable analyses by sex, log FGF23 was associated with SUA in both sexes (β = 0.32, P < 0.01 in males vs. β = 0.20, P = 0.02 in females). Conversely, log FGF23 was independently associated with CUA in males (β = − 0.15, P < 0.01), but not in females (β = − 0.09, P = 0.17). Conclusions FGF23 was independently associated with urate metabolism in this population of CKD patients. FGF23 might also have a stronger association with urate metabolism in males compared with females.
UR - http://www.scopus.com/inward/record.url?scp=84979889688&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84979889688&partnerID=8YFLogxK
U2 - 10.1016/j.metabol.2016.07.005
DO - 10.1016/j.metabol.2016.07.005
M3 - Article
C2 - 27621185
AN - SCOPUS:84979889688
VL - 65
SP - 1498
EP - 1507
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
SN - 0026-0495
IS - 10
ER -
